Alzheimer’s vaccine research has progressed significantly since the disease was first identified over a hundred years ago, with treatments now available that can reduce harmful proteins in the brain associated with the condition. Vaccine trials are currently underway to eliminate these proteins, with one of the most promising candidates being UB-311 developed by American company Vaxxinity. The synthetic, peptide-based immunotherapy has proved safe and tolerable in phase 2 trials and Japanese healthcare company Eisai recently developed LEQEMBI, a cost-effective vaccine for the disease.
News – Scroller Home Page – Kelly Benefits data breach compromised over half a million individuals – teiss
Summarize this content to a maximum of 60 words: News – Scroller Home Page – Kelly Benefits data breach compromised over half a million individuals teiss
